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Available online 17 July 2006494Specific, potent, and sustained short hairpin RNA (shRNA)-mediated gene silencing is crucial for the
successful application of RNA interference technology to therapeutic interventions. We examined
the effects of shRNA expression in primary human lymphocytes (PBLs) using lentiviral vectors
bearing different RNA polymerase III promoters. We found that the U6 promoter is more efficient
than the H1 promoter for shRNA expression and for reducing expression of CCR5 in PBLs. However,
shRNA expression from the U6 promoter resulted in a gradual decline of the transduced cell
populations. With one CCR5 shRNA this decline could be attributed to elevated apoptosis but
another CCR5 shRNA that caused cytotoxicity did not show evidence of apoptosis, suggesting
sequence-specific mechanisms for cytotoxicity. In contrast to the U6 promoter, PBLs transduced by
vectors expressing shRNAs from the H1 promoter could be maintained without major cytotoxic
effects. Since a lower level of shRNA expression appears to be advantageous to maintaining the
shRNA-transduced population, lentiviral vectors bearing the H1 promoter are more suitable for
stable transduction and expression of shRNA in primary human T lymphocytes. Our results suggest
that functional shRNA screens should include tests for both potency and adverse metabolic effects
upon primary cells.Key Words: lentiviral vector, shRNA, RNAi, CCR5, primary T lymphocytes, H1 RNA polymerase III
promoter, U6 RNA polymerase promoterINTRODUCTION
RNA interference (RNAi) using short interfering RNAs
(siRNAs) to inhibit specific gene expression is a powerful
and promising technology for both basic research and
therapeutic intervention. Using a highly conserved
cellular machinery, siRNAs recognize cognate mRNAs
and induce sequence-specific mRNA degradation [1].
Initially, synthetic double-stranded siRNAs, approxi-
mately 21 nucleotides long, were transiently transfected
into mammalian cells to mediate specific RNAi silencing
while avoiding nonspecific global inhibition of gene
expression by the interferon response [2]. Subsequently,
short hairpin RNAs (shRNAs) were devised to be tran-
scribed by RNA polymerase III promoters in mammaliancells [3–7]. shRNAs are processed into siRNA duplexes by
a cellular enzyme called Dicer [8]. The processed siRNA
duplexes are subsequently incorporated into RNA-
induced silencing complexes to guide target mRNA
degradation.
A number of vector systems have been reported to
mediate stable transduction and expression of shRNAs in
mammalian cells [9]. Among them, lentiviral vectors
have the ability to transduce nondividing cells stably
through integration of the vector DNA into the genome
[10]. RNA polymerase III promoters, most commonly the
H1 and U6 promoters, have been incorporated into the
lentiviral vectors for stable expression of shRNAs [11–15].
We and others have utilized such vectors in variousMOLECULAR THERAPY Vol. 14, No. 4, October 2006
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inhibit expression of viral and cellular genes [11–17].
Several recent publications have shown some adverse
effects of expressing shRNAs in mammalian cells. First,
Fish et al. observed significant nonspecific cytotoxic
effects and up-regulation of an interferon-responsive gene,
oligoadenylate synthase-1 (OAS1), in shRNA-transduced
cells [18]. They also reported that target gene silencing
could not be maintained in extended cell culture despite
persistent marker gene expression from the lentiviral
vector in their shRNA-transduced cells. Later, several
reports described type I interferon responses against si/
shRNAs in mammalian cells, even though the length of
the si/shRNA duplexes was less than 30 bp [19,20]. More-
over, some si/shRNA constructs induce down-regulation
of noncognate target genes with less than 100% sequence
homology, resulting in global alterations in gene expres-
sion profiles termed off-target gene effects [21–23]. These
and possibly other adverse outcomes may diminish the
therapeutic potential of the lentiviral vector-mediated
shRNA expression system. Thus, it is important to inves-
tigate the functional consequences of shRNA expression
from lentiviral vectors in mammalian cells and identify
optimal conditions to achieve stable silencing of specific
genes without unintended effects.
In this study, we systematically examined the effective-
ness of gene silencing by shRNAs expressed from two
commonly used H1 and U6 RNA polymerase III promoters.
Further, we studied the long-term effects of lentiviral
vector-mediated shRNA expression in human primary
peripheral blood-derived T lymphocytes (PBLs) cultured
ex vivo and in a NOD/SCID-hu PBL mouse model in vivo.
We obtained a marked reduction of chemokine (C-C
motif) receptor 5 (CCR5) expression in the T lymphocytes
using the U6 promoter ex vivo; however, this was accom-
panied by a gradual decline in the positively transduced
cell population and elevated levels of apoptosis. We also
injected transduced PBLs into NOD/SCID mice to examine
long-term maintenance of RNAi silencing in vivo. Con-
sistent with the ex vivo observations, the U6 promoter
vector-transduced population diminished in the mice.
However, these adverse effects on cell persistence could be
prevented by using H1, a transcriptionally weaker RNA
polymerase III promoter [24], thereby reducing the shRNA
expression level.
RESULTS AND DISCUSSION
U6 Promoter-Driven shRNA Expression Is More Potent
Than That of the H1 Promoter for Reducing CCR5
To determine which RNA polymerase III promoter is
optimal for driving shRNA expression from a lentiviral
vector, we compared directly the effectiveness of the U6
and H1 promoters in reducing CCR5 expression in primary
human T lymphocytes. We designed H1- or U6-driven
shRNA expression cassettes in such a way that identicalMOLECULAR THERAPY Vol. 14, No. 4, October 2006
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lentiviral vectors (see Materials and Methods). We used
our previously reported shRNA targeting nucleotides 186–
205 of the CCR5 coding sequence [designated CCR5-
shRNA (186)] [12] and a new shRNA targeting nucleotides
13–32 [designated CCR5-shRNA (13)]. As controls, we
included an shRNA against firefly luciferase or a null
expression cassette that did not produce a functional
shRNA. As previously reported, the FG12 vector also
expresses the enhanced green fluorescent protein (EGFP)
marker under the human UbiC internal promoter for
tracking transduced cells [12].
We isolated human PBLs from leukopacks, stimulated
them with phytohemagglutinin (PHA) for 2 days, and
transduced them with various lentiviral constructs at an
m.o.i. of 5. Subsequently we cultured transduced PBLs in
the presence of human interleukin-2 (IL-2) and harvested
them at day 7 posttransduction for FACS analysis of CCR5
expression. Because the percentage of the EGFP-positive
(transduced) cell population in each culture was slightly
different, we measured CCR5 expression as the percentage
of CCR5-positive cells within the EGFP+ population (Fig.
1). The U6 promoter-driven CCR5-shRNA (186) and
CCR5-shRNA (13) reduced the fraction of CCR5-express-
ing cells 10- and 25-fold, respectively, compared to the Luc
shRNA controls (Figs. 1a, 1c, and 1e). In contrast, the H1
promoter-driven shRNA-CCR5 (186) and CCR5 (13)
reduced CCR5 expression 3- and 6.5-fold, respectively
(Figs. 1b, 1d, and 1f). Similarly, the mean fluorescence
intensity as an estimate of CCR5 expression was decreased
approximately 5-fold in cells expressing CCR5 shRNA
(186) and (13) by the U6 promoter versus 2- and 4-fold by
CCR5 shRNA (186) and (13), respectively by the H1
promoter (these represent minimum estimates since the
majority of cells are at a background level of fluorescence).
Thus, the U6 promoter is more potent than the H1
promoter for driving shRNA-mediated silencing of CCR5
in primary PBLs.
The U6 Promoter Expresses Higher Levels of shRNA
Than the H1 Promoter
To examine whether CCR5 silencing correlates with the
level of shRNA expression, we measured the level of
shRNA transcripts in CCR5-shRNA (186)- and CCR5-
shRNA (13)-transduced human CEM.NKR-CCR5 cells by
Northern blot analysis. We isolated total cellular RNA
from the CCR5-shRNA-transduced cells at 14 days
posttransduction and detected the antisense strand of
processed CCR5-shRNAs by specific radiolabeled oligo-
nucleotide probes. We found that levels of shRNA
transcripts were at least sixfold higher in the U6
promoter vector-transduced cells than in the H1 pro-
moter vector-transduced cells based on Phosphorimager
quantitation (Fig. 2). The higher level of shRNA tran-
scripts from the U6 promoter correlates with a greater
reduction in CCR5 expression (Supplementary Fig. 1).495
FIG. 1. The U6 promoter is more potent than the H1 promoter in driving the expression of shRNAs in primary human PBLs. PHA/IL-2-stimulated PBLs were
transduced at a m.o.i. of 5 with lentiviral vectors expressing various shRNAs under the control of a U6 or an H1 promoter as indicated. The transduced cells were
further cultured in IL-2-containing medium for 7 days before flow-cytometric analysis for CCR5 and EGFP expression. The x axis indicates GFP expression; the y
axis indicates CCR5 expression of the cell populations in the live cell gate. Each graph shows the CCR5/EGFP plot from the U6- and the H1-shRNA vector-
transduced PBLs for each shRNA against CCR5 (186) (a, b), CCR5 (13) (c, d), or firefly luciferase (e, f). (g) Cells transduced with vector without shRNA expression
unit (no shRNA) and (h) mock-transduced PBLs are also shown. The quadrant lines were defined by mock transduction (h) and isotype-control stain. Percentage
CCR5 positivity and mean fluorescence intensity (MFI) of CCR5 in the EGFP-positive population are shown at the top. The percentage of cells in each quadrant is
also indicated. The data are representative of four independent experiments. The U6-shRNA vector-transduced PBLs had a greater CCR5 reduction than H1-
shRNA vector-transduced PBLs in the four experiments (P = 0.004) by the Wilcoxon rank sum test.
ARTICLE doi:10.1016/j.ymthe.2006.05.015This result, combined with the CCR5 reduction data in
primary PBL (Fig. 1), suggests that a higher level of
shRNA expression induces a more effective reduction in
CCR5 expression. Passage of transduced CEM.NKR-CCR5
cells over 4 weeks showed stable EGFP expression and
no apparent cytotoxicities (data not shown), in contrast
to what we observed in primary PBL (see below).
Stable Maintenance of Transduced PBLs Using H1
Promoter Driven shRNA Vectors
To investigate the persistence of shRNA expression by
lentiviral vector and the long-term effects of shRNA
expression on cell growth, we examined the kinetics of
total cell numbers in the U6- and H1-promoter shRNA-
transduced PBLs at three time points during culture (Fig.4963A). We noted a significant decline in total cell numbers
in all U6-shRNA-transduced cell cultures. The presence or
absence of target mRNA in shRNA-transduced cells did
not affect the decline of cell number, since it occurred for
shRNAs against CCR5 (with target) and firefly luciferase
and LacZ (without target). Next, we measured the
percentage of EGFP+ cells in each vector-transduced PBL
culture (Fig. 3B). Consistently, the percentage EGFP+
population in all U6-shRNA-transduced PBLs declined
more rapidly over time. In contrast, the EGFP+ popula-
tion persisted in the H1-shRNA-transduced PBLs
although a slight decline was observed at the later time
points.
To examine further whether the loss of EGFP+ cells was
a consequence of a loss of vector-transduced cells, weMOLECULAR THERAPY Vol. 14, No. 4, October 2006
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FIG. 2. The U6 promoter expresses higher levels of shRNA than the H1 promoter. CEM.NKR-CCR5 cells were transduced at an m.o.i. of 1 with lentiviral vectors
bearing either the U6 or the H1 promoter. As CEM.NKR-CCR5 cells are fivefold more susceptible to lentiviral vector transduction than primary PBLs, we used an
m.o.i. of 1 to achieve a similar percentage EGFP expression between CEM.NKR-CCR5 and primary PBLs. The transduced cells were cultured for 12 days and total
RNA was isolated from the cells. The total RNA was blotted with probes against the CCR5-shRNA (186) or (13). Known amounts of synthetic CCR5-siRNAs (186)
or (13) were blotted in parallel as standards for the quantitation. The data are representative of two independent experiments.
ARTICLEdoi:10.1016/j.ymthe.2006.05.015measured the average copy number of vector DNA in
transduced cells at the three time points. We isolated
total cellular DNA from the transduced PBLs and sub-
jected it to real-time quantitative DNA PCR analysis using
a primer pair specific to the vector sequence. We used
human h-globin quantitative PCR to normalize the
amount of cellular DNA in each sample. Table 1 shows
normalized vector copy numbers per cell at each time
point. Corresponding to the loss of total cell counts and
the EGFP+ population, the amount of vector DNA
decreased more rapidly in the U6-shRNA-transduced PBLs
relative to the H1-shRNA or no-shRNA vector-transduced
PBLs. The average copy number of the U6-shRNA vector
DNA in transduced PBLs decreased approximately 10-fold
between day 4 and day 12, much greater than the drop in
total cell counts (Fig. 3A) and the percentage of EGFP+
cells (Fig. 3B). This might reflect a preferential loss of cells
with multiple copies of vector integration in which
higher levels of shRNA expression might result in a
greater impact on cell growth.MOLECULAR THERAPY Vol. 14, No. 4, October 2006
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Transduced PBLs
We examined the type I interferon (IFN) response in the
shRNA-transduced PBLs as a possible cause of the decline
in U6-shRNA-transduced PBL populations. Activation of
interferon responses has been reported to cause attenu-
ated cell growth and apoptosis [25]. Although the stem
sequences of our shRNAs are designed to yield a 19-bp
RNA duplex after Dicer processing, several recent reports
suggested that some shRNAs with less than 30-bp stems
can activate IFN-responsive genes [19,20,26]. To analyze
whether IFN-responsive genes were induced in the U6-
shRNA- and H1-shRNA-transduced PBLs, we measured
the mRNA levels for OAS1 and interferon stimulated
gene-15 kDa (ISG15), two common IFN-responsive genes.
We isolated total cellular RNA from transduced PBLs 4
days posttransduction and subjected it to Northern blot
analysis using probes for OAS1 and ISG15 sequences (Fig.
4). Although poly(I:C) electroporation induced both
OAS1 and ISG15 gene expression up to 9.5-fold, we could497
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TABLE 1: Loss of vector DNA copy number in U6-promoter-
driven shRNA-expressing primary PBLs
Vector
Vector DNA copies per cell
Day 4 Day 7 Day 12
H1-CCR5-shRNA (186) 3.8 2.5 2.6
U6-CCR5-shRNA (186) 4.8 2.3 0.3
H1-CCR5-shRNA (13) 2.5 2.4 1.2
U6-CCR5-shRNA (13) 3.3 1.6 0.4
H1-luc-shRNA 3.2 1.7 1.0
U6-luc-shRNA 3.5 1.0 0.4
H1-lacZ-shRNA 3.7 3.0 1.9
U6-lacZ-shRNA 3.8 2.1 0.4
No shRNA 1.5 0.8 0.6
Mock b0.01 b0.01 b0.01
Total DNA was isolated from various lentiviral vector-transduced PBLs at days 4, 7, and 12
posttransduction and subjected to real-time DNA PCR analysis for lentiviral vector DNA
sequence and human h-globin. The vector DNA copy number was normalized to human h-
globin copy number in each sample and expressed as vector DNA copies per cell.
ARTICLEdoi:10.1016/j.ymthe.2006.05.015not detect significant up-regulation of OAS1 or ISG15
expression in the shRNA-transduced cells. Based on these
observations, we conclude that the loss of U6-shRNA-
transduced PBLs was unlikely to be related to a general
IFN-mediated response.
U6 Promoter-Driven shRNA Expression Can Cause
Elevated Apoptosis in Primary PBLs
We next examined whether the cells underwent accel-
erated apoptosis. We harvested transduced PBLs at 7 and
12 days posttransduction and stained them with Annexin
V to measure apoptosis. We calculated the percentage of
EGFP+ cells that were also Annexin V positive as
measured by FACS analysis and compared the Annexin
V positivity of U6- and H1-shRNA-transduced cells (Table
2). We observed two- to fourfold higher percentages of
Annexin V+ cells in populations transduced by U6-shRNA
vectors against CCR5 shRNA (186), firefly luciferase, and
LacZ in several independent experiments.
We examined the loss of EGFP-positive cells and
apoptotic effects in more detail by infection at different
multiplicities of viral vector and analysis at more time
points. Consistent with the results of Fig. 3B, we observed
declines in the percentage of EGFP+ cells when CCR5
shRNA was driven by the U6 promoter, but not when
CCR5 shRNA was driven by the H1 promoter (Supple-
mentary Fig. 2A). At the higher m.o.i. both CCR5 shRNAsFIG. 3. (A) Slower cell growth of PBLs expressing U6-promoter-driven shRNA. Ve
days posttransduction. After each cell count, cells were divided 1:3 and fresh med
the U6-shRNA vector-transduced PBLs for shRNA against CCR5 (186) (a), CCR5 (
with vector that did not express shRNA. (B) Decline in EGFP-positive population i
monitored by FACS analysis in the shRNA-transduced PBLs at days 4, 7, and 12 po
H1- and the U6-shRNA vector-transduced PBLs for shRNA against CCR5 (186) (
transduced with vector that did not express shRNA. The data are representative o
overall greater decrease (greater negative slope) than H1-shRNA vector-transduc
MOLECULAR THERAPY Vol. 14, No. 4, October 2006
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samples over time we observed significant apoptosis only
with CCR5-shRNA (186) and not with CCR5-shRNA (13),
despite reductions in percentage EGFP+ cells over time
with both shRNAs (Supplementary Fig. 2B). We observed
slightly more apoptosis over time in cells transduced at
the higher m.o.i. We observed no significant apoptosis
for either shRNA when expressed using the H1 promoter.
These results suggest that high level expression of shRNA
from the U6 promoter may lead to elevated apoptosis in
human PBLs, providing one explanation for the decline
in the U6-shRNA-transduced cells. However, since CCR5-
shRNA (13) expression from the U6 promoter did lead to
a decline in EGFP+ cells, but was not associated with
elevated apoptosis, apoptosis appears not to be the only
underlying mechanism for cytotoxicity.
IFN-; Production Was Not Altered by shRNA
Expression
Although we observed increased apoptosis in the U6-
shRNA-transduced PBLs, the majority of transduced PBLs
still remained Annexin V negative and maintained
reduced CCR5 expression levels, indicating that the
GFP+/Annexin V cell population might still be func-
tionally intact. To test this hypothesis, we examined
whether the transduced PBLs were capable of responding
to a T cell stimulus and producing the effector cytokine
IFN-g. Seven and 12 days posttransduction, we stimu-
lated the transduced PBLs with phorbol 12-myristate 13-
acetate (PMA)/ionomycin for 4 h in the presence of
brefeldin A. We permeabilized the cells and stained them
for intracellular IFN-g. We calculated the percentage of
EGFP-positive cells that were also IFN-g positive (Supple-
mentary Table1). We observed high levels of IFN-g
production with H1- and U6-shRNA and control vector-
transduced cells, and there was no significant difference
in the frequency of the IFN-g+ population among them.
Thus, this study shows that at least one key T cell
functional response was intact in the shRNA-transduced
PBLs.
H1 Promoter-Driven shRNA Reduced CCR5 in a
NOD/SCID-hu PBL Model
The life span of PHA/IL-2-activated PBLs restricts in vivo
experiments to a rather short time period (12 days). To
investigate further the long-term effects of shRNA expres-
sion in human primary PBLs, we utilized a NOD/SCID-huctor-transduced PBLs were plated at 50  104/ml and counted at 4, 7, and 12
ium was added. Each graph shows the cell count (104/ml) from the H1- and
13) (b), firefly luciferase (c), or LacZ (d). No shRNA indicates cells transduced
n primary PBLs expressing U6-promoter-driven shRNA. EGFP populations were
st-vector transduction. Each graph shows percentage EGFP positivity from the
a), CCR5 (13) (b), firefly luciferase (c), or LacZ (d). No shRNA indicates cells
f four independent experiments. The U6-shRNA vector-transduced PBL had an
ed PBL in the four experiments ( P = 0.0001) by the Wilcoxon rank sum test.
499
TABLE 2: U6-promoter-driven shRNA expression causes
elevated apoptosis in primary PBLs
% Annexin V+ cells in the EGFP+ population
Experiment 1 Experiment 2
Vector Day 7 Day 7 Day 12
H1-CCR5-shRNA (186) 3.8 4.2 6.7
U6-CCR5-shRNA (186) 10.2 13.0 24.1
H1-CCR5-shRNA (13) 1.6 3.5 5.5
U6-CCR5-shRNA (13) 3.2 3.9 5.5
H1-luc-shRNA 3.0 7.3 7.2
U6-luc-shRNA 7.0 11.3 11.8
H1-lacZ-shRNA 4.4 9.4 7.6
U6-lacZ-shRNA 10.0 9.3 13.9
No shRNA 3.5 6.6 6.9
Cells were transducedwith lentiviral vectors expressing shRNAs under the control of theU6 o
H1 promoter as described for Fig. 1 and underMaterials andMethods. At the indicated time
posttransduction, cells were analyzed by FACS for apoptotic cells (Annexin V positive) in th
EGFP-expressing population. The numbers indicate the percentage of cells that are both
Annexin V and EGFP positive. Different donor PBLs were used for experiments 1 and 2.
FIG. 4. IFN-induced genes OAS1 and ISG15 are not up-regulated in shRNA-transduced PBLs. RNA was isolated from transduced PBLs 4 days posttransduction and
subjected to Northern blot analysis using specific probes for human OAS1 and ISG15. As a control, poly(I:C) was transfected into PBLs by electroporation. The
data are representative of two independent experiments.
ARTICLE doi:10.1016/j.ymthe.2006.05.015PBL model [27]. The absence of a functional immune
system in NOD/SCID mice permits long-term engraftment
(30 days) of human PBLs in the mouse blood circulation.
In this setting, the engrafted human PBLs are also highly
stimulated by mouse antigens, resulting in a high level of
CCR5 expression and enabling us to examine shRNA-
mediated CCR5 silencing. We injected H1- or U6-CCR5-
shRNA (13)-transduced PBLs into the mice through an
intraperitoneal route and analyzed peripheral blood at 30
days postinjection for CCR5 and EGFP expression within
the human CD45-positive lymphocyte population. Rep-
resentative FACS data are shown in Fig. 5; quantitative
analysis of the FACS results from all animals is summarized
in Table 3. In four of four animals reconstituted with PBLs
transduced with a no-shRNA vector control, 38–56% of
human CD45-positive cells expressed EGFP (Table 3).
Likewise, 27 and 30% of human CD45-positive cells
were EGFP+ in two of four animals injected with the
human PBLs transduced with H1-CCR5-shRNA (13).
The other two animals of this group did not have
human CD45-positive cells due to the lack of human
cell engraftment. In contrast, four of four animals
injected with the U6-CCR5-shRNA (13)-transduced
human PBLs had less than 1.5% EGFP+ cells in the
engrafted human CD45-positive cells. Thus, in agree-
ment with the ex vivo experiments, U6-driven shRNA500expression resulted in a remarkably low percentage of
EGFP-expressing cells, presumably due to a cell growth
disadvantage.
To examine whether CCR5 expression was reduced in
the H1-CCR5-shRNA (13)-transduced PBLs, we measured
the level of CCR5 reduction in the EGFP+ population.MOLECULAR THERAPY Vol. 14, No. 4, October 2006
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FIG. 5. Reduction of CCR5 in NOD SCID-Hu PBL model. PBLs (1  107) transduced with the lentiviral vector expressing shRNA as indicated were injected into
NOD SCID mice. Peripheral blood was obtained from the mice at 30 days postinjection and treated with red blood cell lysis buffer and the remaining cells were
analyzed by FACS for human CD45 and CCR5 expression. The human CD45-positive population was gated and analyzed for EGFP and CCR5 expression. The
percentage CCR5 positivity in the EGFP-positive population was calculated and is shown at the top. The percentage of cells in each quadrant is also shown. The
data shown are a representative flow-cytometric analysis data set. N/A, not applicable.
ARTICLEdoi:10.1016/j.ymthe.2006.05.015CCR5 expression was reduced two- to fourfold in the H1
promoter-driven shRNA-transduced PBLs relative to the
no-shRNA vector-transduced PBLs (compare animals 1
and 2 with animals 9, 10, 11, and 12 in Table 3 and the
representative data shown in Fig. 5). Taken together, we
conclude that the H1 promoter is more suitable than the
U6 promoter for stable shRNA expression against CCR5
in human lymphocytes in vivo.
In summary, we systematically examined the func-
tional consequences of shRNA-lentiviral vector trans-
duction and the expression of shRNA in human primary
peripheral blood lymphocytes in in vivo culture and in a
NOD/SCID-hu PBL mouse model. Although U6-pro-
moter-driven shRNA inhibited CCR5 to a greater extent
than H1-promoter-driven shRNA, we observed a gradual
decline in the EGFP+ population and total cell numbers
in the U6-shRNA-expressing PBLs, accompanied by a
decline in the copy number of U6-shRNA vector DNA.
For one of the CCR5 shRNAs these effects could be at
least partly attributed to elevated apoptotic cell death.
With H1-promoter-driven shRNA, the cell number and
EGFP+ population were steadily maintained with onlyMOLECULAR THERAPY Vol. 14, No. 4, October 2006
Copyright C The American Society of Gene Therapyminor decreases in levels of transduced cells, and no
increase in apoptosis was detected. These results suggest
that a high level of continuous shRNA expression might
have adverse effects on cell growth in human primary
PBLs, partly due to increased apoptosis. Based on these
observations, we conclude that it is important to control
the level of shRNA expression to maintain stable gene
silencing. We thus propose that the H1 promoter is a
better choice for lentiviral-shRNA expression in human
primary PBLs. However, the lower level of shRNA
expression by the H1 promoter resulted in inefficient
reduction of CCR5 gene expression; to achieve efficient
reduction of target gene expression, highly potent
shRNAs must be identified. Based on our results and
other published results, the potency of an shRNA is
largely dependent on its primary sequence [12,28].
Several rational design and library screening methods
have been proposed for selecting efficient shRNA
sequence for gene silencing [28–30], but it remains
important to screen a large number of potential shRNAs.
We anticipate further systematic screening will yield even
more potent shRNAs against CCR5 but potential cyto-501















H1-CCR5-shRNA (13) 73.5 1 84.8 27.7 1.9 25.8 7.0
2 73.6 22.1 2.0 20.1 9.0
3 0.02 b0.01
4 0.5 b0.01
U6-CCR5-shRNA (13) 62.3 5 88.3 0.4 0.1 0.3
6 63.9 0.8 0.1 0.7
7 40.5 0.6 0.2 0.3
8 38.2 1.5 0.3 1.2
No shRNA 73.4 9 84.2 45.9 7.9 38.0 17.0
10 32.9 56.3 12.1 44.2 22.0
11 90.8 38.6 11.7 27.0 30.0
12 81.7 45.5 10.1 35.5 22.0







Lentiviral vector-transduced PBLs (1  107) were injected into NOD/SCID mice. Peripheral blood was obtained from the mice at 30 days postinjection and treated with red blood cell lysis
buffer and the remaining cells were analyzed by FACS for human CD45 and CCR5 expression. Mouse 17 did not receive human PBLs (mock injection).
ARTICLE doi:10.1016/j.ymthe.2006.05.015toxic effects must be evaluated empirically even when a
weaker promoter such as H1 is utilized.
RNAi technology has been widely applied for reduc-
ing specific target gene expression and may be used as a
therapeutic intervention in the future. For silencing
CCR5 as a therapy for AIDS, stable shRNA expression is
critical in preventing HIV-1 entry. Although lentiviral
vectors are well suited to stable expression of shRNA in
mammalian cells, high-level shRNA expression from the
human U6 promoter caused a progressive loss of the
transduced human PBLs. Such undesirable effects will
impede the advancement of this technology into clinical
applications. In accordance with our observations, sev-
eral groups reported cytotoxicity associated with shRNA
expression in mammalian cells [18,31,32]. In contrast,
other reports did not report any obvious toxicities from
U6-promoter-driven shRNAs [24,33,34]. Given the vari-
ability of data in different cell types and experimental
settings, we propose that the best approach to identify-
ing suitable shRNAs for any given target gene is to select
multiple shRNA sequences having the desired functional
effect and test them empirically in the context of
different expression cassettes for adverse metabolic
effects upon cells. Furthermore, given that cytotoxicity
was observed only in primary PBLs and not in a T cell
line (CEM.NKR-CCR5), it is important to design assays
using primary cells.
It is noteworthy that two shRNAs directed against
CCR5 show distinct phenotypes. Both CCR5-shRNA (186)
and CCR5-shRNA (13) are potent at suppressing CCR5
expression. Both shRNAs induce cytotoxic effects as502evidenced by loss of EGFP+ transduced cells over time.
Yet, only CCR5-shRNA (186) shows obvious proapoptotic
effects. These results indicate that there are likely to be
multiple mechanisms for cytotoxicity induced by shRNAs
and that these effects are likely to be dependent on the
primary sequence of the shRNA.
At present, we do not fully understand the mecha-
nisms behind elevated cytotoxicity in the U6-shRNA-
transduced PBLs. Induction of the IFN response has been
reported to cause slower cell growth [25], and several
reports have shown induction of type I interferon
response by introducing si/shRNA into mammalian cells
[19,20,26]. On the other hand, other reports suggest no
induction of type I interferon responses by shRNAs [2]. In
our study, we did not detect significant induction of IFN-
responsive genes OAS1 and ISG15. Bridge et al. initially
reported that U6- and H1-promoter-driven shRNA expres-
sion from a lentiviral vector caused over 500-fold
induction of OAS1 gene expression in human lung
fibroblasts when two vectors were used concomitantly
[19]. However, in a subsequent publication, they showed
the IFN response was caused by a flawed vector design;
removing additional AA dinucleotides and preserving the
transcriptional start site with a consensus C/G sequence
at position 1/+1 prevented the OAS1 induction [35].
Our shRNA design is a 19-nt stem coupled with the intact
cognate C/G at the U6 promoter transcriptional start site.
This could explain why we did not observe activation of
IFN-responsive genes.
Another possible mechanism underlying the adverse
effects caused by the overexpression of shRNA from aMOLECULAR THERAPY Vol. 14, No. 4, October 2006
Copyright C The American Society of Gene Therapy
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microRNA (miRNA) pathways. Mammalian cells express
more than 200 endogenous miRNAs, which are structur-
ally similar to shRNA [36]. Some miRNAs appear to play
important roles in regulating differentiation and develop-
ment processes at the posttranscriptional level [37,38].
The same cellular machinery is utilized for shRNA
processing and maturation [39,40]. We postulate that
overexpression of shRNA from strong promoters might
compete with endogenous miRNAs for limiting cellular
factors, thus interfering with normal miRNA function.
Consistent with this notion, Yi et al. recently reported
that both miRNAs and shRNAs were stabilized and
exported to the cytoplasm by karyopherin exportin 5.
Exportin 5 expression was shown to be at very low
abundance and appeared be one of the limiting factors
for RNAi process in human cells [41].
Another possible mechanism is off-target gene silen-
cing by shRNAs. Microarray analysis data revealed that si/
shRNA expression may cause a global change in gene
expression profiles [21–23]. In addition, several reports
showed that si/shRNA causes down-regulation of non-
cognate genes with some degree of sequence homology.
The off-target effects were siRNA sequence specific, in
both concentration-dependent and concentration-inde-
pendent manners [21–23]. Although this study does not
provide any direct evidence, it is possible that global
changes in gene expression may cause adverse effects on
cell growth.
While the RNAi technology holds great promise for
potential therapeutic applications such as AIDS therapy,
careful optimization of shRNA expression in target cells is
necessary. We still do not fully understand the mecha-
nisms underpinning the loss of transduced cells express-
ing high levels of shRNAs. Nevertheless, our results
demonstrate that such an adverse effect can be avoided,
and further studies should provide us with more infor-
mation and bring us closer to applying RNAi technology
in human clinical settings.MATERIALS AND METHODS
Vector construction. Human H1-RNA polymerase III promoter DNA
(241 to 9) was amplified from HEK-293 genomic DNA with primers
5V-CCATGGAATTCGAACGCTGACGTC-3V and 5V-GCAAGCTTTTG-
GATCCGTGGTCTCATACAGAACTTATAAGATTCCC-3V, containing a
novel 3V BamHI site for the insertion of shRNA sequences at the +1
position of the H1 transcript. The PCR fragment was cloned into the pBS-
SKII plasmid (Stratagene) between the XbaI and XhoI sites (designated
pBS-H1-3). The cloning of a human U6-RNA pol III promoter, the
sequence of the CCR5-shRNA (186), and the shRNA against lacZ were
previously described [12]. The new CCR5-shRNA (13) was designed to
target nucleotide position 13–31 of the human CCR5 coding sequence
(GenBank Accession No. U57840). The firefly luciferase shRNA was
designed to target nucleotide position 1915–1933 of the firefly luciferase
gene. Each shRNA was inserted downstream of a human U6 promoter in
the FG12 lentiviral vector as previously described [12]. To construct H1-
promoter-driven shRNA expression cassettes, two complementary DNAMOLECULAR THERAPY Vol. 14, No. 4, October 2006
Copyright C The American Society of Gene Therapyoligos were synthesized, annealed, and inserted between the BamHI and
XhoI sites of pBS-hH1-3, immediately downstream of an H1 promoter: 5V-
GATCCCC(N)19TTCAAGAGA(N)19TTTTTC-3V, 3V-GGG(N)19AAGTTCTCT
(N)19AAAAAGAGCT-5V. The 19-nt sense and reverse complementary
targeting sequences are highlighted in bold. The shRNA cassette also
features a TTCAAGAGA loop situated between the sense and the reverse
complementary targeting sequences and a TTTTT terminator at the 3Vend.
To construct the shRNA-expressing lentiviral vectors, the shRNA expres-
sion cassette was subcloned into the FG12 plasmid between the XbaI and
XhoI sites. The resulting plasmids were confirmed by restriction enzyme
digestion and DNA sequencing.
Lentiviral vector production. All vesicular stomatitis virus G-protein-
pseudotyped lentiviral vector stocks were produced by calcium phosphate-
mediated transient transfection of HEK-293T cells, as previously described
[12,42].
Cell culture. CEM.NKR-CCR5 [43] (AIDS Research and Reference Reagent
Program of the National Institutes of Health) were maintained in IscoveTs
MEM, 10% FCS. Human primary PBLs were isolated from leukopacks by
Ficoll and cultured in RPMI 1640 medium, 20% FCS, with 2.5 Ag of PHA,
100 units of penicillin, 100 Ag/ml streptomycin for 2 days. After 2 days of
PHA stimulation, PBLs were cultured in RPMI 1640 medium containing
20 units/ml IL-2.
Vector transduction. Human PBLs were isolated from leukopacks by
Histopaque (Sigma) and cultured in RPMI 1640 medium, 20% FCS, with
2.5 Ag of PHA (Murex Biotech, Dartford, UK)/100 units of penicillin/100
Ag/ml streptomycin for 2 days. After 2 days of PHA stimulation, PBLs were
used for lentiviral vector transduction. Briefly, 50  104 cells were
incubated with various lentiviral vectors at an m.o.i. of 5 for 2 h in the
presence of 8 Ag/ml Polybrene. After the incubation, virus supernatants
were removed and replaced with 1.5 ml of fresh RPMI 1640 medium, 20%
FCS containing 20 units/ml IL-2 (Roche Molecular Biochemicals). The
transduced cells were harvested 4, 7, and 12 days later and stained with
APC-labeled mouse anti-human CCR5 mAb (2D7; PharMingen) or a
mouse IgG2a/k isotype control (OX-35; PharMingen), according to the
manufacturerTs instructions. GFP and CCR5 expression was analyzed by
FACS at multiple time points after transduction.
Real-time DNA PCR. DNA was isolated from lentiviral vector-transduced
PBL by urea lysis, as previously described [44]. Quantitative, real-time
DNA PCR was performed as previously described [45] using a primer/
probe pair that amplifies cellular h-globin sequences and one that
amplifies HIV-1 DNA (R-U5 of the LTR). All amplifications were
performed on the ABI Prism 7700 (Applied Biosystems).
Northern blot analysis. Total RNA was isolated using Tri Reagent
(Invitrogen). For small RNA blotting analysis, 50 Ag of the RNA samples
was resolved on a 10% denaturing polyacrylamide gel containing 50%
urea. Subsequently the gel was transferred to a Hybond Plus membrane
(Amersham) using TransBlotter (Bio-Rad). Hybridization was performed
using 32P-labeled oligonucleotide probe against the antisense strand of
CCR5 (186) or (13). The membranes were also hybridized with a probe
against 5S rRNA for loading control. To generate the standard curves for
quantitation, known amounts of oligonucleotide of the corresponding
antisense strand were loaded on the same gel. Radioactive signal was
measured by PhosphoImager (Storm; Amersham). For regular Northern
blot analysis, RNA samples were resolved on a 1% agarose gel and then
transferred to a Genescreen membrane (NEN). Hybridization was
performed using 32P-labeled cDNA probes against human OSA1 and
ISG15 in a sequential manner after the previous probe was stripped. The
membrane was also hybridized with a oligonucleotide probe against 18S
rRNA for loading control.
Annexin V staining. Lentiviral vector-transduced cells (1  105) were
harvested from cell cultures and incubated with PE-conjugated anti-
Annexin V monoclonal antibodies for 30 min according to the man-
ufacturerTs manual (BD Biosciences). The stained cells were analyzed
immediately by FACS analysis using FACSCalibur (Becton–Dickinson).503
ARTICLE doi:10.1016/j.ymthe.2006.05.015IFN-g production and intracellular IFN-g staining. Lentiviral vector-
transduced cells were restimulated with 5 ng/ml PMA (Sigma–Aldrich)
and 0.5 Ag/ml ionomycin (Sigma–Aldrich), in the presence of 10 Ag/ml
brefeldin A (Sigma) for 4 h. After the incubation, the cells were fixed with
2% paraformaldehyde, permeabilized by saponin, and subjected to
intracellular staining with PE-conjugated anti-human IFN-g antibody.
NOD/SCID-hu PBL mouse model. NOD/LtSz-Prkdc scid/J mice were
purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and
maintained in the BSL3 SCID mouse facility at UCLA. Mice were treated
with 1 mg of TMh-1 anti-mouse interleukin 2 receptor h chain mono-
clonal antibodies to deplete mouse NK cells 1 day before human PBL
injection. Lentiviral vector-transduced PBLs (1  107 cells in 0.5 ml of
RPMI 1640 containing 20% fetal calf serum per mouse) were injected into
the peritoneal cavity. Mouse peripheral blood was obtained from the
retro-orbital plexus 30 days post-cell injection. The blood was treated with
red blood cell lysis buffer and remaining cells were subjected to
monoclonal antibody staining for human CD45, CCR5.
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Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.ymthe.2006.
05.015.
REFERENCES
1. Hannon, G. J. (2002). RNA interference. Nature 418: 244 –251.
2. Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (2001).
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian
cells. Nature 411: 494 – 498.
3. Lee, N. S., et al. (2002). Expression of small interfering RNAs targeted against HIV-1 rev
transcripts in human cells. Nat. Biotechnol. 20: 500 – 505.
4. Miyagishi, M., and Taira, K. (2002). U6 promoter driven siRNAs with four uridine 3V
overhangs efficiently suppress targeted gene expression in mammalian cells. Nat.
Biotechnol. 20: 497 –500.
5. Brummelkamp, T. R., Bernards, R., and Agami, R. (2002). A system for stable expression
of short interfering RNAs in mammalian cells. Science 296: 550 –553.
6. Paul, C. P., Good, P. D., Winer, I., and Engelke, D. R. (2002). Effective expression of
small interfering RNA in human cells. Nat. Biotechnol. 20: 505 –508.
7. Yu, J. Y., DeRuiter, S. L., and Turner, D. L. (2002). RNA interference by expression of
short-interfering RNAs and hairpin RNAs in mammalian cells. Proc. Natl. Acad. Sci. USA
99: 6047 –6052.
8. Bernstein, E., Caudy, A. A., Hammond, S. M., and Hannon, G. J. (2001). Role for a
bidentate ribonuclease in the initiation step of RNA interference.Nature 409: 363 –366.
9. Wadhwa, R., Kaul, S. C., Miyagishi, M., and Taira, K. (2004). Vectors for RNA
interference. Curr. Opin. Mol. Ther. 6: 367 –372.
10. Naldini, L., et al. (1996). In vivo gene delivery and stable transduction of nondividing
cells by a lentiviral vector. Science 272: 263 – 267.
11. Abbas-Terki, T., Blanco-Bose, W., Deglon, N., Pralong, W., and Aebischer, P. (2002).
Lentiviral-mediated RNA interference. Hum. Gene Ther. 13: 2197 –2201.
12. Qin, X. F., An, D. S., Chen, I. S., and Baltimore, D. (2003). Inhibiting HIV-1 infection in
human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5.
Proc. Natl. Acad. Sci. USA 100: 183 –188.
13. Tiscornia, G., Singer, O., Ikawa, M., and Verma, I. M. (2003). A general method for
gene knockdown in mice by using lentiviral vectors expressing small interfering RNA.
Proc. Natl. Acad. Sci. USA 100: 1844 –1848.
14. Rubinson, D. A., et al. (2003). A lentivirus-based system to functionally silence genes in
primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat.
Genet. 33: 401 – 406.
15. Banerjea, A., et al. (2003). Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in504T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived
macrophages. Mol. Ther. 8: 62 –71.
16. Ahmed, R., Hahn, C. S., Somasundaram, T., Villarete, L., Matloubian, M., and Strauss,
J. H. (1991). Molecular basis of organ-specific selection of viral variants during chronic
infection. J. Virol. 65: 4242 –4247.
17. Li, M. J., et al. (2003). Inhibition of HIV-1 infection by lentiviral vectors expressing Pol
III-promoted anti-HIV RNAs. Mol. Ther. 8: 196 –206.
18. Fish, R. J., and Kruithof, E. K. (2004). Short-term cytotoxic effects and long-term
instability of RNAi delivered using lentiviral vectors. BMC Mol. Biol. 5: 1 –15.
19. Bridge, A. J., Pebernard, S., Ducraux, A., Nicoulaz, A. L., and Iggo, R. (2003).
Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet.
34: 263 –264.
20. Sledz, C. A., Holko, M., de Veer, M. J., Silverman, R. H., and Williams, B. R. (2003).
Activation of the interferon system by short-interfering RNAs.Nat. Cell Biol. 5: 834 –839.
21. Persengiev, S. P., Zhu, X., and Green, M. R. (2004). Nonspecific, concentration-
dependent stimulation and repression of mammalian gene expression by small
interfering RNAs (siRNAs). RNA 10: 12 –18.
22. Jackson, A. L., et al. (2003). Expression profiling reveals off-target gene regulation by
RNAi. Nat. Biotechnol. 21: 635 –637.
23. Scacheri, P. C., et al. (2004). Short interfering RNAs can induce unexpected and
divergent changes in the levels of untargeted proteins in mammalian cells. Proc. Natl.
Acad. Sci. USA 101: 1892 –1897.
24. Makinen, P. I., et al. (2006). Stable RNA interference: comparison of U6 and H1
promoters in endothelial cells and in mouse brain. J. Gene Med. 8: 433 –441.
25. Stark, G. R., Kerr, I. M., Williams, B. R., Silverman, R. H., and Schreiber, R. D. (1998).
How cells respond to interferons. Annu. Rev. Biochem. 67: 227 –264.
26. Kariko, K., Bhuyan, P., Capodici, J., and Weissman, D. (2004). Small interfering RNAs
mediate sequence-independent gene suppression and induce immune activation by
signaling through toll-like receptor 3. J. Immunol. 172: 6545 –6549.
27. Koyanagi, Y., et al. (1997). Primary human immunodeficiency virus type 1 viremia
and central nervous system invasion in a novel hu-PBL-immunodeficient mouse strain.
J. Virol. 71: 2417 –2424.
28. Mittal, V. (2004). Improving the efficiency of RNA interference in mammals. Nat. Rev.
Genet. 5: 355 –365.
29. Naito, Y., Yamada, T., Ui-Tei, K., Morishita, S., and Saigo, K. (2004). siDirect: highly
effective, target-specific siRNA design software for mammalian RNA interference.
Nucleic Acids Res. 32: W124 –W129.
30. Reynolds, A., Leake, D., Boese, Q., Scaringe, S., Marshall, W. S., and Khvorova, A.
(2004). Rational siRNA design for RNA interference. Nat. Biotechnol. 22: 326 –330.
31. Cao, W., Hunter, R., Strnatka, D., McQueen, C. A., and Erickson, R. P. (2005). DNA
constructs designed to produce short hairpin, interfering RNAs in transgenic mice
sometimes show early lethality and an interferon response. J. Appl. Genet. 46: 217 – 225.
32. Gasior, S. L., Palmisano, M., and Deininger, P. L. (2005). Alu-linked hairpins efficiently
mediate RNA interference with less toxicity than do H1-expressed short hairpin RNAs.
Anal. Biochem. 349: 41 –48.
33. Robbins, M. A., et al. (2006). Stable expression of shRNAs in human CD34(+)
progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat.
Biotechnol. 24: 566 –571.
34. Seibler, J., et al. (2005). Single copy shRNA configuration for ubiquitous gene
knockdown in mice. Nucleic Acids Res. 33: 1 –10.
35. Pebernard, S., and Iggo, R. D. (2004). Determinants of interferon-stimulated gene
induction by RNAi vectors. Differentiation 72: 103 – 111.
36. Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell
116: 281 –297.
37. Poy, M. N., et al. (2004). A pancreatic islet-specific microRNA regulates insulin
secretion. Nature 432: 226 –230.
38. Ambros, V. (2004). The functions of animal microRNAs. Nature 431: 350 – 355.
39. Zeng, Y., Yi, R., and Cullen, B. R. (2003). MicroRNAs and small interfering RNAs can
inhibit mRNA expression by similar mechanisms. Proc. Natl. Acad. Sci. USA 100:
9779 –9784.
40. Doench, J. G., Petersen, C. P., and Sharp, P. A. (2003). siRNAs can function as miRNAs.
Genes Dev. 17: 438 – 442.
41. Yi, R., Doehle, B. P., Qin, Y., Macara, I. G., and Cullen, B. R. (2005). Overexpression of
exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs.
RNA 11: 220 –226.
42. An, D. S., Qin, X. F., Auyeung, V. C., Baltimore, D., and Chen, I. S. Y. (2005). Lentiviral
vector mediated delivery of si/shRNA. In Gene Silencing by RNA Interference: Technology
and Application (M. Sohail, Ed.), pp. 111 –126. CRC Press, Boca Raton, FL.
43. Trkola, A., Matthews, J., Gordon, C., Ketas, T., and Moore, J. P. (1999). A cell line-based
neutralization assay for primary human immunodeficiency virus type 1 isolates that use
either the CCR5 or the CXCR4 coreceptor. J. Virol. 73: 8966 –8974.
44. Zack, J. A., Arrigo, S. J., Weitsman, S. R., Go, A. S., Haislip, A., and Chen, I. S. (1990).
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile,
latent viral structure. Cell 61: 213 – 222.
45. Gorry, P. R., et al. (2001). Macrophage tropism of human immunodeficiency virus type
1 isolates from brain and lymphoid tissues predicts neurotropism independent of
coreceptor specificity. J. Virol. 75: 10073 –10089.MOLECULAR THERAPY Vol. 14, No. 4, October 2006
Copyright C The American Society of Gene Therapy
